MedTrace Logo

GRK4 Polymorphisms Blood Pressure Response to Candesartan

NCT01629225 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2014-11-18

No results posted yet for this study

Summary

The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

Conditions

  • Essential Hypertension

Interventions

DRUG

Candesartan

To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension

Sponsors & Collaborators

  • Third Military Medical University

    lead OTHER

Principal Investigators

  • Zeng Chunyu, Doctor · TMMU

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01629225 on ClinicalTrials.gov